<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390182</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00042314</org_study_id>
    <nct_id>NCT00390182</nct_id>
  </id_info>
  <brief_title>Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)</brief_title>
  <acronym>GCC0319</acronym>
  <official_title>GCC 0319: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Department of Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        1. To assess the maximum tolerated dose of low-dose UART(Upper Abdominal Radiation Therapy
           ) or WART(Whole Abdominal Radiation Therapy) given in combination with standard fixed
           dose-rate Gemcitabine in patients with advanced gastrointestinal (GI) or ovarian tumors
           (Phase I).

        2. To assess response rate and survival in advanced upper GI tumors following completion of
           therapy (Phase II).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before entering this study the doctor will examine the patient and order blood tests. These
      tests will use approximately 10 ml of blood. Blood work should be done within 3 weeks prior
      to treatment.. Women of child-bearing potential are required to have a pregnancy test done
      within 7 days prior to the start of treatment . A CT or a PET/CT scan of the chest, abdomen
      and pelvis will be done within 4 weeks prior to starting treatment . All subjects
      participating in this study will receive radiation therapy and chemotherapy. Patients will
      get 4 cycles of chemotherapy along with radiation. Each cycle of chemotherapy consists of
      gemcitabine given i.v. on day 1 and day 8 of treatment. XRT is given on days 1 and 2 and on
      days 8 and 9 twice a day. This works out to 8 treatments of XRT per course of chemo. Overall,
      a total of 32 treatments of radiation therapy will be given during the 4 sessions of
      chemotherapy. Blood work for CBC with differential and platelets will be done prior to each
      dose of chemotherapy.The investigational portion of this study is the radiation therapy given
      to the abdomen on the same day and the day after the patient receives chemotherapy.
      Three-Four weeks after treatment completion the patient will be evaluated again. The treating
      physician will examine the patient and order blood tests. These tests will use approximately
      10 ml of blood. The physician will also order a repeat CT or PET/CT to compare the disease
      status after treatment. These tests are not experimental and are part of routine check-ups of
      patients with pancreatic cancer. Patients will be followed for survival. Protected health
      information will not be reviewed by someone other than the patient's provider to identify
      potential subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>3 weeks</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Distant Mestastases - Liver</measure>
    <time_frame>Participants were followed for an average of 8 years</time_frame>
    <description>Patients with distant mestastases to the liver</description>
  </other_outcome>
  <other_outcome>
    <measure>Time of Advanced/Recurrent Disease Without Distant Metastases.</measure>
    <time_frame>Participants were followed for an average of 8 years</time_frame>
    <description>Locally advanced/recurrent disease without distant metastases.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Gastrointestinal Neoplasms</condition>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.
Radiation: External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.
Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.
**Radiation is the experimental part of the study.</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Radiation:External Radiation Therapy</other_name>
    <other_name>**Radiation is the experimental part of the study.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients are eligible if they have newly diagnosed histologically confirmed locally
             advanced or metastatic tumors of the pancreas. Patients must be felt to be
             unresectable by surgical criteria or felt to be medically inoperable. Patients may
             also be Stage IV with metastatic disease to the liver. Patients with bone and/or lung
             metastasis may be included at the investigators discretion.

          2. Patients must have measurable disease by CT scan.

          3. Patients must be able to give informed consent. Patients must be older than 18 years
             of age.

          4. Patients should have adequate bone marrow, renal, and hepatic function including:
             Bilirubin less than 1.25 x institutional normal LDH SGPT, SGOT, and alkaline
             phosphatase less than3 x institutional normal Serum creatinine less than or equal to 3
             mg/dl. Absolute neutrophil count of greater than 1500 Hemoglobin greater than 9 gm per
             dl Platelet count greater than 100,000 WBC greater than 3000 cells per mcl

          5. Women of child-bearing potential must be agreeable to adequate contraception.(hormonal
             or barrier method of birth control) prior to study entry and for the duration of study
             participation.)

          6. Patients must have a Karnofsky performance status of greater than or equal 60 or
             Zubrod of less or equal to 2.

          7. Life expectancy of at least 3 months.

          8. May have had a second malignancy or multiple malignancies if adequately controlled by
             clinical means. patients with more than one type of cancer must be cleared by the
             principal investigator.

          9. Patients must be at least 1 week from any major operative procedure.

        10 .Patients may have brain metastasis if these brain metastasis are well controlled by
        usual clinical criteria and if the life expectancy is at least 3 months. Any patient with
        brain metastasis must be cleared by the principal investigator.

        Exclusion Criteria:

          1. Active infection requiring intravenous (IV) antibiotics at the time of entry.

          2. Cerebral metastasis which has not been adequately controlled.

          3. Significant malnutrition, cachexia, inundation or inability to give informed consent
             by clinical assessment.

          4. Concurrent chemotherapy not prescribed in this protocol.

          5. Any significant medical problems such as diabetes, cardiomyopathy or hypertension
             which is not reasonably controlled

          6. Prior radiation or chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Regine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chair - University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland &amp; Baltimore VA medical centre</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2006</study_first_posted>
  <results_first_submitted>January 16, 2013</results_first_submitted>
  <results_first_submitted_qc>April 7, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2014</results_first_posted>
  <last_update_submitted>April 7, 2014</last_update_submitted>
  <last_update_submitted_qc>April 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Department of Radiation Oncology</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>GI tumors</keyword>
  <keyword>Locally Advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Hepatobiliary</keyword>
  <keyword>Ovary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Digestive System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All patients with cancer are seen by a multi-discipline clinic (medical, surgical, radiotherapy, etc). The PI or Co-PI identifies eligible candidates and initiates the discussion of research participation.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Gem(1250mg/m2, d1, 8) +LDFRT (60cGy/fx BID, d1,2,8,9)</title>
          <description>4 cycles (1 cycle = 21 days): Gemcitabine 1250/m2 given IV Day 1 and Day 8; with concurrent Low Dose Fractionated Radiation Therapy (LDFRT). The total Radiation dose would be 19.2 Gy divided over 32 fractions. Treatment will be given in 2 fractions with a minimum 4 hr inter-fraction interval, not to exceed 6 hours. Radiotherapy given after the initiation of Gemcitabine Days 1,2,8, and 9.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Chemotherapy, Gemcitabine With Concurrent Low Dose Ra</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="38"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>3 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Fractionated Radiation Therapy (LDFRT) + Gemcitabine</title>
            <description>Use of LDFRT with systemic gemcitabine is safe, tolerable, and potentially effective. In advanced pancreatic cancer, where response rates with single agent gemcitabine have been low, this chemopotentiation paradigm may improve survival among a poor prognostic patient cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2.7" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Distant Mestastases - Liver</title>
        <description>Patients with distant mestastases to the liver</description>
        <time_frame>Participants were followed for an average of 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Fractionated Radiation Therapy (LDFRT) + Gemcitabine</title>
            <description>Use of LDFRT with systemic gemcitabine is safe, tolerable, and potentially effective. In advanced pancreatic cancer, where response rates with single agent gemcitabine have been low, this chemopotentiation paradigm may improve survival among a poor prognostic patient cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Distant Mestastases - Liver</title>
          <description>Patients with distant mestastases to the liver</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="45" upper_limit="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Time of Advanced/Recurrent Disease Without Distant Metastases.</title>
        <description>Locally advanced/recurrent disease without distant metastases.</description>
        <time_frame>Participants were followed for an average of 8 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Low Dose Fractionated Radiation Therapy (LDFRT) + Gemcitabine</title>
            <description>Use of LDFRT with systemic gemcitabine is safe, tolerable, and potentially effective. In advanced pancreatic cancer, where response rates with single agent gemcitabine have been low, this chemopotentiation paradigm may improve survival among a poor prognostic patient cohort.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Advanced/Recurrent Disease Without Distant Metastases.</title>
          <description>Locally advanced/recurrent disease without distant metastases.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Standard Chemotherapy, Gemcitabine With Concurrent Low Dose Ra</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic</sub_title>
                <description>Hematologic toxicities, (combined any WBC, HGB, PLTs, ANC) grade 4 experienced in 17 out of 38 participants.</description>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>Non-neutropenic</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - non-neutropenic</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nancy Kennedy</name_or_title>
      <organization>University of Maryland Baltimore</organization>
      <phone>410-328-2513</phone>
      <email>nkennedy@umm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

